We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety, and other CNS diseases and disorders with high unmet need. Lead candidate, AV-101, is currently in Phase 2 for the treatment of major depressive disorder. PH94B and PH10 are being prepared for Phase 3 for the treatment of social anxiety disorder and MDD, respectively.